Article Details
Retrieved on: 2021-04-19 18:44:04
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on SAGE Therapeutics (SAGE), with a price target of ...
Article found on: www.smarteranalyst.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here